Exelixis (EXEL) Beats Q2 Earnings Estimates

Exelixis (EXEL) came out with quarterly earnings of $0.75 per share, beating the Zacks Consensus Estimate of $0.65 per share. This compares to earnings of $0.84 per share a year ago. These figures are adjusted for non- recurring items. Over the last four quarters, the company has surpassed consensus EPS estimates four times. Exelixis, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $568.26 million for the quarter ended June 2025, missing the Zacks Consensus Estimate ...